Use for the shortest time required to achieve control of asthma symptoms. Long-term use may be considered only in patients whose asthma cannot be adequately controlled on asthma controller medications. Taper dose when discontinuing treatment. Take maintenance dose as prescribed even when asymptomatic. Rinse mouth w/ water after inhalations to minimise risk of oropharyngeal thrush. Do not use to initiate treatment w/ inhaled steroids in patients being transferred from oral steroids. Potential systemic effects of inhaled corticosteroids eg, HPA axis depression/adrenal insufficiency, bone density reduction, cataract & glaucoma, & growth rate retardation in childn & adolescents. Signs of existing infection may be masked by high-dose glucocorticosteroid use & new infections may appear during use. Consider arrhythmogenic potential of β2
-agonists before commencing treatment for bronchospasm. Patients w/ pre-existing CV conditions may be at greater risk of developing adverse CV effects following administration. High doses of β2
-agonists can result to potentially serious hypokalaemia. Blood-glucose increasing effects of β2
-stimulants; extra blood glucose controls are recommended in DM patients. Possible development of pneumonia in patients w/ COPD. Patients w/ active or quiescent pulmonary TB or fungal, bacterial or viral resp infections. Patients w/ increased susceptibility to sympathomimetic amines (eg, inadequately controlled hyperthyroidism). Patients w/ severe CV disorders eg, ischaemic heart disease, tachyarrhythmias or severe heart failure. Patients w/ renal or hepatic impairment. Pregnancy & lactation. 160/4.5 mcg & 320/9 mcg
Not recommended for childn <12 yr.